T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.

T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.

Diğer sürümleri göster (1)

Campath-1G is an immunosuppressive monoclonal antibody directed against human lymphocytes. Its effectiveness in preventing graft-versus-host disease (GVHD) by simple opsonisation of bone marrow T-cells has been studied in 36 consecutive allografts: in 17 for leukaemia, one for essential thrombocytos...

Detaylı Bibliyografya
Asıl Yazarlar:	Jacobs, P, Wood, L, Fullard, L, Waldmann, H, Hale, G
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	1994

Benzer Materyaller

T-CELL DEPLETION BY EXPOSURE TO CAMPATH-1G IN-VITRO PREVENTS GRAFT-VERSUS-HOST DISEASE
Yazar:: Jacobs, P, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Ex vivo T-cell depletion of bone marrow grafts with campath 1 prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation.
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect.
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

CAMPATH-1 FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT-REJECTION - SUMMARY OF RESULTS FROM A MULTI-CENTRE STUDY
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1988)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
Yazar:: Willemze, R, ve diğerleri
Baskı/Yayın Bilgisi: (1992)

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).
Yazar:: Waldmann, H, ve diğerleri
Baskı/Yayın Bilgisi: (1984)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1988)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
Yazar:: Heit, W, ve diğerleri
Baskı/Yayın Bilgisi: (1986)

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Yazar:: Kottaridis, P, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Yazar:: Williams, R, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
Yazar:: Apperley, J, ve diğerleri
Baskı/Yayın Bilgisi: (1986)

Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo.
Yazar:: Cobbold, S, ve diğerleri
Baskı/Yayın Bilgisi: (1986)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

T-cell depletion of stem cell grafts with campath-1H "in the bag" followed by cyclosporin immunosuppression remains a cost effective strategy in transplantation
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

CAMPATH: from concept to clinic.
Yazar:: Waldmann, H, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
Yazar:: Chakrabarti, S, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
Yazar:: Newman, D, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

What can be done to prevent graft versus host disease?
Yazar:: Waldmann, H, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

Specificity of monoclonal antibody Campath-1.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1988)

RESULTS OF T-CELL DEPLETION WITH CAMPATH-1 IN BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL)
Yazar:: Apperley, J, ve diğerleri
Baskı/Yayın Bilgisi: (1985)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

Availability of Campath-1 antibodies for bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
Yazar:: Buggins, A, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.
Yazar:: Slavin, S, ve diğerleri
Baskı/Yayın Bilgisi: (1985)

CAMPATH-1H in inflammatory arthritis.
Yazar:: Watts, R, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

The CAMPATH-1 antigen (CDw52).
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1990)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
Yazar:: Friend, P, ve diğerleri
Baskı/Yayın Bilgisi: (1991)

PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION
Yazar:: Slavin, S, ve diğerleri
Baskı/Yayın Bilgisi: (1985)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
Yazar:: Fibbe, W, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease
Yazar:: Haitham Abdelhakim, ve diğerleri
Baskı/Yayın Bilgisi: (2017-06-01)

Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
Yazar:: Waldmann, H, ve diğerleri
Baskı/Yayın Bilgisi: (1987)

CAMPATH-IH in multiple sclerosis.
Yazar:: Moreau, T, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
Yazar:: Hamblin, M, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
Yazar:: Lim, S, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

CAMPATH-1 antibodies in stem-cell transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (2001)